全文获取类型
收费全文 | 11436篇 |
免费 | 815篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 253篇 |
妇产科学 | 426篇 |
基础医学 | 1499篇 |
口腔科学 | 389篇 |
临床医学 | 1043篇 |
内科学 | 2496篇 |
皮肤病学 | 198篇 |
神经病学 | 919篇 |
特种医学 | 406篇 |
外国民族医学 | 3篇 |
外科学 | 1876篇 |
综合类 | 241篇 |
一般理论 | 4篇 |
预防医学 | 591篇 |
眼科学 | 113篇 |
药学 | 594篇 |
1篇 | |
中国医学 | 47篇 |
肿瘤学 | 1123篇 |
出版年
2023年 | 69篇 |
2022年 | 44篇 |
2021年 | 303篇 |
2020年 | 185篇 |
2019年 | 254篇 |
2018年 | 317篇 |
2017年 | 219篇 |
2016年 | 264篇 |
2015年 | 300篇 |
2014年 | 384篇 |
2013年 | 489篇 |
2012年 | 816篇 |
2011年 | 796篇 |
2010年 | 438篇 |
2009年 | 378篇 |
2008年 | 652篇 |
2007年 | 715篇 |
2006年 | 595篇 |
2005年 | 611篇 |
2004年 | 596篇 |
2003年 | 512篇 |
2002年 | 511篇 |
2001年 | 343篇 |
2000年 | 337篇 |
1999年 | 333篇 |
1998年 | 96篇 |
1997年 | 104篇 |
1996年 | 66篇 |
1995年 | 65篇 |
1994年 | 77篇 |
1993年 | 61篇 |
1992年 | 163篇 |
1991年 | 153篇 |
1990年 | 123篇 |
1989年 | 143篇 |
1988年 | 76篇 |
1987年 | 118篇 |
1986年 | 80篇 |
1985年 | 55篇 |
1984年 | 67篇 |
1983年 | 42篇 |
1982年 | 26篇 |
1981年 | 30篇 |
1980年 | 26篇 |
1979年 | 46篇 |
1976年 | 30篇 |
1975年 | 22篇 |
1974年 | 29篇 |
1972年 | 25篇 |
1971年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Filippo Pietrantonio Christian Cotsoglou Giovanni Fucà Salvatore Lo Vullo Federico Nichetti Massimo Milione Jorgelina Coppa Marta Vaiani Alessandra Alessi Michele Prisciandaro Michele Droz-Dit Busset Federica Morano Salvatore Corallo Silvia Lazzati Maria Antista Alessia Mennitto Giovanni Randon Alessandra Raimondi Vincenzo Mazzaferro 《Clinical colorectal cancer》2019,18(1):34-43.e6
Background
In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response.Patients and Methods
This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features. Patients received 5 preoperative and 4 postoperative cycles of biweekly COI-B (irinotecan 180 mg/m2 and bevacizumab 5 mg/Kg on day 1, oxaliplatin 85 mg/m2 on day 2, and capecitabine 1000 mg/m2 twice a day on days 2 to 6). The primary endpoint was pathologic response rate in the intention-to-treat population. A Simon 2-stage design was adopted to detect an increase from 30% to 50% with a power of 90%. Dynamic imaging biomarkers (early tumor shrinkage [ETS], deepness of response, maximum standardized uptake volume [SUVmax]/regression index) and next generation sequencing data were explored as surrogates.Results
From June 2013 to March 2017, 46 patients were enrolled. Pathologic response was achieved in 63% patients (endpoint met), and responders achieved significantly better survival outcomes with respect to non-responders. The most frequent grade 3/4 adverse events were diarrhea and neutropenia (8.7%) in the preoperative phase and thromboembolic events (5.9%) in the postoperative phase. ETS and lower SUV-2 were significantly associated with pathologic response.Conclusion
The COI-B regimen is a feasible and highly active perioperative strategy in patients with molecularly unselected, potentially resectable CRCLM. ETS and SUV-2 have a promising role as imaging-based biomarkers for pathologic response. 相似文献4.
5.
6.
Deborah N. N. Lo‐Fo‐Wong Hanneke C. J. M. de Haes Neil K. Aaronson Doris L. van Abbema Mathilda D. den Boer Marjan van Hezewijk Marcelle Immink Ad A. Kaptein Marian B. E. Menke‐Pluijmers Anna K. L. Reyners Nicola S. Russell Manon Schriek Sieta Sijtsema Geertjan van Tienhoven Mathilde G. E. Verdam Mirjam A. G. Sprangers 《Psycho-oncology》2020,29(3):539-549
7.
8.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
9.
Evaluation of training nurses to perform semi‐automated three‐dimensional left ventricular ejection fraction using a customised workstation‐based training protocol 下载免费PDF全文
10.
Honlok Lo Po-Yin Shen Po-Chih Shen Pei-Hsi Chou Cheng-Chang Lu 《The Journal of emergency medicine》2019,56(2):201-204